F. P. Veras

This study shows ultrasound can reduce SARS-CoV-2 infectivity in vitro without causing heat or cavitation.

This study shows that inhibiting C5aR1 signaling reduces neutrophil extracellular traps and improves lung pathology in COVID-19.

This study shows that DNase I treatment reduces NETs and organ injury in a COVID-19 mouse model.

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

Pyronaridine reduces SARS-CoV-2 viral load and lung pathology in mice, with in vitro inhibition of viral PLpro and host kinase CAMK1.

This study investigates SARS-CoV-2 infection of human lymphomononuclear cells in vitro and in vivo, finding that monocytes, B cells, and T cells are susceptible to infection and viral replication.